News & Media Catch up with our latest releases here. Filter Article 56 Podcast 3 Video 26 Rita Ray 16/08/2024 Rita Ray 16/08/2024 10/07 Our CEO, Clarissa Sowemimo-Coker speaking at HLTH Europe 2024 Video interview Read More Rita Ray 16/08/2024 Rita Ray 16/08/2024 28/06 We are hiring! Head of Drug Discovery and Development Read More Rita Ray 16/08/2024 Rita Ray 16/08/2024 08/05 British Biotech OCTP shares (Oxford Cannabinoid) delisting from LSE Read More Rita Ray 16/08/2024 Rita Ray 16/08/2024 15/04 Oxford Cannabinoid Technologies Appoint CRO en route to Phase I Trials for Programme Two Read More Rita Ray 14/08/2024 Rita Ray 14/08/2024 11/04 Appointment of Phase I Clinical Trial CRO Appointment of Phase I Clinical Trial CRO Read More Rita Ray 05/04/2024 Rita Ray 05/04/2024 OCT Company Update with Doceo OCT Company Update with Doceo Read More Rita Ray 05/04/2024 Rita Ray 05/04/2024 OCT’s Elevator Pitch with Doceo Read More Rita Ray 04/04/2024 Rita Ray 04/04/2024 The importance of patents Read More Rita Ray 04/04/2024 Rita Ray 04/04/2024 Cornerstone investor Cantheon is kudos for OCT Read More Rita Ray 04/04/2024 Rita Ray 04/04/2024 OCT Secures £1.205m to Advance Phase I Clinical Trial for Programme Two Video interview Read More
Rita Ray 16/08/2024 Rita Ray 16/08/2024 10/07 Our CEO, Clarissa Sowemimo-Coker speaking at HLTH Europe 2024 Video interview Read More
Rita Ray 16/08/2024 Rita Ray 16/08/2024 28/06 We are hiring! Head of Drug Discovery and Development Read More
Rita Ray 16/08/2024 Rita Ray 16/08/2024 08/05 British Biotech OCTP shares (Oxford Cannabinoid) delisting from LSE Read More
Rita Ray 16/08/2024 Rita Ray 16/08/2024 15/04 Oxford Cannabinoid Technologies Appoint CRO en route to Phase I Trials for Programme Two Read More
Rita Ray 14/08/2024 Rita Ray 14/08/2024 11/04 Appointment of Phase I Clinical Trial CRO Appointment of Phase I Clinical Trial CRO Read More
Rita Ray 05/04/2024 Rita Ray 05/04/2024 OCT Company Update with Doceo OCT Company Update with Doceo Read More
Rita Ray 04/04/2024 Rita Ray 04/04/2024 OCT Secures £1.205m to Advance Phase I Clinical Trial for Programme Two Video interview Read More
